01655nas a2200253 4500008004100000022001400041245015600055210006900211260009300280300001200373490000700385520069100392653000801083653001901091653001501110653002601125653002301151653001101174100002901185700002501214700002601239700002501265856011101290 2010 eng d a1469-066700aDiscovery of rifampicin as a new anti-glycating compound by matrix-assisted laser desorption/ionization mass spectrometry-based insulin glycation assay0 aDiscovery of rifampicin as a new antiglycating compound by matri a6 CHARLTON MILL, CHARLTON, CHICHESTER,, W SUSSEX PO18 0HY, ENGLANDbIM PUBLICATIONScFEB a221-2260 v163 a
An in vitro insulin glycation assay was developed for screening glycation inhibitors. The assay involves the use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for monitoring the formation of glycated insulin. The assay is simple, rapid and amenable for high throughput screening. Using this assay we have discovered a strong anti-glycation activity for the anti-tuberculosis drug rifampicin. These results were compared with bovine serum albumin glucose fluorescence assay. In addition, the IC(50) of rifampicin was lower than that of aminoguanidine, a known anti-glycating agent, suggesting that rifampicin is a more potent glycation inhibitor.
10aAGE10aaminoguanidine10aantibiotic10adiabetic complication10adrug repositioning10aIC(50)1 aGolegaonkar, Sandeep, B.1 aBhonsle, Hemangi, S.1 aBoppana, Ramanamurthy1 aKulkarni, Mahesh, J. uhttp://library.ncl.res.in/content/discovery-rifampicin-new-anti-glycating-compound-matrix-assisted-laser-0